- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 303486, 9 pages
Molecular Characterization of TP53 Gene in Human Populations Exposed to Low-Dose Ionizing Radiation
1Laboratory of Human and Medical Genetics, Biological Sciences Institute, Federal University of Pará (UFPA), Augusto Correa Street, Number 01, CEP 66075-110 Belém, PA, Brazil
2Epstein-Barr Virus Laboratory, Virology Section, Evandro Chagas Institute, BR-316 Highway Km 7, CEP 67030-000 Ananindeua, PA, Brazil
3Human Cytogenetics Laboratory, Biological Sciences Institute, Federal University of Pará (UFPA), Augusto Correa Street, Number 01, CEP 66075-110 Belém, PA, Brazil
Received 1 November 2012; Revised 19 December 2012; Accepted 24 December 2012
Academic Editor: Thomas Liehr
Copyright © 2013 Igor Brasil-Costa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. T. Natarajan, “Mechanisms for induction of mutations and chromosome alterations,” Environmental Health Perspectives, vol. 101, no. 3, pp. 225–229, 1993.
- A. T. Natarajan, “Techniques for biomonitoring of human populations for genetic effects,” Revista Brasileira de Genetica, vol. 16, no. 3, pp. 841–847, 1993.
- R. Iyer and B. E. Lehnert, “Effects of ionizing radiation in targeted and nontargeted cells,” Archives of Biochemistry and Biophysics, vol. 376, no. 1, pp. 14–25, 2000.
- I. D. Louro, J. C. Llerena Jr., M. S. Vieira de Melo, P. Ashton-Prolla, and N. Conforty-Fróes, Genética Molecular do Cancer, MSG Produção Editorial, São Paulo, Brazil, 2nd edition, 2002.
- W. W. Au, G. S. Wilkinson, S. K. Tyring et al., “Monitoring populations for DNA repair deficiency and for cancer susceptibility,” Environmental Health Perspectives, vol. 104, no. 3, pp. 579–584, 1996.
- D. Pawel, D. Preston, D. Pierce, and J. Cologne, “Improved estimates of cancer site-specific risks for A-bomb survivors,” Radiation Research, vol. 169, no. 1, pp. 87–98, 2008.
- A. Bleise, P. R. Danesi, and W. Burkart, “Properties, use and health effects of depleted uranium (DU): a general overview,” Journal of Environmental Radioactivity, vol. 64, no. 2-3, pp. 93–112, 2003.
- A. Camacho, R. Devesa, I. Vallés et al., “Distribution of uranium isotopes in surface water of the Llobregat river basin (Northeast Spain),” Journal of Environmental Radioactivity, vol. 101, no. 12, pp. 1048–1054, 2010.
- K. Servomaa and T. Rytomaa, ActivAtion of Oncogenes By UrAnium Aerosols: A in Vitro Study, J B Reytan, New York, NY, USA, 1989.
- K. Servomaa and T. Rytomaa, “Malignant transformation of mouse fibroblasts by uranium aerosols released from Chernobyl,” in Frontiers in Radiation Biology, E. Riklis, Ed., pp. 229–234, Balaban Publishers, Weinheim, Germany, 1990.
- A. C. Miller, W. F. Blakely, D. Livengood et al., “Transformation of human osteoblast cells to the tumorigenic phenotype by depleted uranium-uranyl chloride,” Environmental Health Perspectives, vol. 106, no. 8, pp. 465–471, 1998.
- M. Brown, “Toxicological assessments of Gulf War veterans,” Philosophical Transactions of the Royal Society B, vol. 361, no. 1468, pp. 649–679, 2006.
- S. Milacic, D. Petrovic, D. Jovicic, R. Kovacevic, and J. Simic, “Examination of the health status of population from depleted-uranium-contaminated regions,” Environmental Research, vol. 95, pp. 2–10, 2004.
- A. Patel, “Health in the Middle East: no strong link between depleted uranium and cancer,” British Medical Journal, vol. 333, article 971.3, 2006.
- INB-Nuclear Industries of Brazil, 2009, http://www.inb.gov.br/.
- GenBank, 2010, http://www.ncbi.nlm.nih.gov/.
- IBGE, “Brazilian Institute of Geography and Statistics: Brazilian maps,” 2011, http://www.ibge.gov.br/ibgeteen/mapas/index.html.
- NASA, “National Aeronautics and Space Administration: Satellite photo made in 2002,” 2011, http://visibleearth.nasa.gov/view_rec.php?id=2433.
- V. P. Melo, Avaliação da Concentração do 222Rn Nos Ambientes Internos e Externos em Residêncas do Município de MontE Alegre, PA, Instituto de Biofísica Carlos Chagas Filho, Rio de Janeiro, Brazil, 1999.
- B. Ponnaiya, G. Jenkins-Baker, A. Bigelow, S. Marino, and C. R. Geard, “Detection of chromosomal instability in α-irradiated and bystander human fibroblasts,” Mutation Research, vol. 568, no. 1, pp. 41–48, 2004.
- N. Geva-Zatorsky, N. Rosenfeld, S. Itzkovitz et al., “Oscillations and variability in the p53 system,” Molecular Systems Biology, vol. 2, article 33, 2006.
- A. Efeyan and M. Serrano, “p53: guardian of the genome and policeman of the oncogenes,” Cell Cycle, vol. 6, no. 9, pp. 1006–1010, 2007.
- M. Oren and V. Rotter, “Introduction. p53: the first twenty years,” Cellular and Molecular Life Sciences, vol. 55, no. 1, pp. 9–11, 1999.
- L. A. Donehower, M. Harvey, B. L. Slagle et al., “Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours,” Nature, vol. 356, no. 6366, pp. 215–221, 1992.
- B. Vogelstein, D. Lane, and A. J. Levine, “Surfing the p53 network,” Nature, vol. 408, no. 6810, pp. 307–310, 2000.
- G. Alsbeih, N. Al-Harbi, M. Al-Buhairi, K. Al-Hadyan, and M. Al-Hamed, “Association between TP53 codon 72 single-nucleotide polymorphism and radiation sensitivity of human fibroblasts,” Radiation Research, vol. 167, no. 5, pp. 535–540, 2007.
- K. Szymańska and P. Hainaut, “TP53 and mutations in human cancer,” Acta Biochimica Polonica, vol. 50, no. 1, pp. 231–238, 2003.
- C. V. de Moura Gallo, G. Azevedo e Silva Mendonça, E. de Moraes, M. Olivier, and P. Hainaut, “TP53 mutations as biomarkers for cancer epidemiology in Latin America: current knowledge and perspectives,” Mutation Research: Reviews in Mutation Research, vol. 589, no. 3, pp. 192–207, 2005.
- A. Petitjean, E. Mathe, S. Kato et al., “Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database,” Human Mutation, vol. 28, no. 6, pp. 622–629, 2007.
- O. Brant, M. Hoffmann, A. Kanappilly, T. Görögh, and S. Gottschlich, “p53 codon 72 polymorphism in squamous cell carcinoma of the head and neck region,” Anticancer Research, vol. 27, no. 5, pp. 3301–3305, 2007.
- A. Fernández-Rubio, M. F. López-Cima, P. González-Arriaga et al., “The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain,” Lung Cancer, vol. 61, no. 3, pp. 309–316, 2008.
- Z. Cao, J. H. Song, Y. K. Park et al., “The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients,” Neoplasma, vol. 56, no. 2, pp. 114–118, 2009.
- V. Lazar, F. Hazard, F. Bertin, N. Janin, D. Bellet, and B. Bressac, “Simple sequence repeat polymorphism within the p53 gene,” Oncogene, vol. 8, no. 6, pp. 1703–1705, 1993.
- S. Wang-Gohrke, H. Becher, R. Kreienberg, I. B. Runnebaum, and J. Chang-Claude, “Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years,” Pharmacogenetics, vol. 12, no. 3, pp. 269–272, 2002.
- F. Gemignani, V. Moreno, S. Landi et al., “A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA,” Oncogene, vol. 23, no. 10, pp. 1954–1956, 2004.
- X. Wu, H. Zhao, C. I. Amos et al., “p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity,” Journal of the National Cancer Institute, vol. 94, no. 9, pp. 681–690, 2002.
- R. Birgander, A. Själander, A. Rannug et al., “P53 polymorphisms and haplotypes in lung cancer,” Carcinogenesis, vol. 16, no. 9, pp. 2233–2236, 1995.